Get the Stockscreener App
19.79
18.65%
3.11
After Hours:
20.09
0.30
+1.52%
Forte Biosciences Inc stock is traded at $19.79, with a volume of 277.67K.
It is up +18.65% in the last 24 hours and up +323.00% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
See More
Previous Close:
$16.68
Open:
$17.5
24h Volume:
277.67K
Relative Volume:
0.57
Market Cap:
$24.39M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-17.06
EPS:
-1.16
Net Cash Flow:
$-28.71M
1W Performance:
+46.05%
1M Performance:
+323.00%
6M Performance:
+36.51%
1Y Performance:
+77.33%
1-Day Range:
$16.86
$23.36
1-Week Range:
$10.11
$23.36
52-Week Range:
$4.11
$23.36
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
19.79 | 24.39M | 0 | -31.48M | -28.71M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com India
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com UK
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 data - Endpoints News
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Forte Biosciences secures $53 million in funding By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Forte Biosciences Secures $53M for FB102 Advancements - TipRanks
Forte Biosciences Shares Are Soaring Today: What's Going On? - Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results - Benzinga
Forte Biosciences secures $53 million in funding - Investing.com India
Forte Biosciences More Than Doubles on $53M Private Placement - MarketWatch
Stock Market News: Forte Biosciences +151.47%, Exicure +99.48% among top gainers during mid day trading - Business Upturn
Stock Market News: Ethan Allen Interiors down by 90.10% while Exicure gains 99.48% during mid day trading - Business Upturn
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views - Benzinga
Stock Market Today: Forte Biosciences up by 54.60% while Red Cat Holdings gains 35% in early trading - Business Upturn
Stock Market Today: Ethan Allen Interiors falls by nearly 90% while Forte Biosciences surges by 64.89% in early trading - Business Upturn
US Stocks Mostly Lower; Target Posts Downbeat Earnings - Benzinga
Thrive Tribe Technologies Affirms ASX Compliance Amid Stock Query - MSN
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications - The Bakersfield Californian
Forte Biosciences Secures $53M Private Placement for Autoimmune Drug Development | FBRX Stock News - StockTitan
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
IBD Rating Upgrades: Chesapeake Utilities Flashes Improved Relative Price Strength - MSN
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - Lelezard
Forte Biosciences, Inc. announced that it expects to receive $53 million in funding from OrbiMed Advisors LLC, Janus Henderson Group plc, Tybourne Capital Management Limited, Ikarian Capital, LLC, BVF Partners L.P., Fred Alger Management, LLC - Marketscreener.com
When the Price of (FBRX) Talks, People Listen - Stock Traders Daily
Psyence Biomedical gets extension to show compliance with Nasdaq’s listing rules - MSN
Brown Advisory US Smaller Companies PLC Updates Office Location - MSN
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Forte Biosciences (NASDAQ:FBRX) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Forte Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Perceptive Advisors LLC Acquires Shares in Forte Biosciences Inc - GuruFocus.com
Wolfe Research Initiates Coverage of Bristol-Myers Squibb CompanyPreferred Security (BMYMP) with Peer Perform Recommendation - MSN
Forte Biosciences Inc (FBRX) Quarterly 10-Q Report - Quartzy
Forte Biosciences Inc. Reports Q3 2024 Earnings - TipRanks
Tocagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Forte Biosciences Advances Celiac Disease Trial as Q3 Losses Widen to $4.54/Share | FBRX Stock News - StockTitan
Upwork (UPWK) Now Trades Above Golden Cross: Time to Buy? - MSN
Head to Head Analysis: Sycamore Entertainment Group (OTCMKTS:SEGI) & Forte Biosciences (NASDAQ:FBRX) - Defense World
Dallas-Based MODE Global Acquires Jillamy’s Freight Brokerage Division - dallasinnovates.com
Stock Traders Purchase Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
Traders Buy Large Volume of Call Options on Alaska Air Group (NYSE:ALK) - Defense World
Avadel Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AVDL) - Defense World
Wendy’s Target of Unusually High Options Trading (NASDAQ:WEN) - Defense World
Traders Buy High Volume of Call Options on Guidewire Software (NYSE:GWRE) - Defense World
Patterson-UTI Energy Sees Unusually Large Options Volume (NASDAQ:PTEN) - Defense World
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
197,819 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,881,627 |
| Chen Hubert C | See remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
7,500 |
0 |
96,478 |
| Riley Antony A | Chief Financial Officer |
Jan 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
192,285 |
| Wagner Paul A. | See Remarks |
Jan 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,854,486 |
| Wagner Paul A. | See Remarks |
Dec 18 '23 |
Buy |
0.75 |
10,000 |
7,525 |
1,823,236 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):